Skip to main content
. 2011 Aug 24;118(17):4567–4576. doi: 10.1182/blood-2011-05-355594

Figure 2.

Figure 2

Duration of CHR and MCyR with bosutinib treatment. Duration of CHR (A) and MCyR (B) were determined by the evaluable population; patients entering the study in CCyR were excluded. As of the data cutoff, 77% of the evaluable patients who achieved a CHR still retained their response (124/172 [72%] imatinib-resistant and 65/75 [87%] imatinib-intolerant patients), with a median duration of CHR not reached. Of the evaluable patients who achieved a MCyR, 78% still retained their MCyR as of the data cutoff (73/101 [72%] imatinib-resistant and 36/39 [92%] imatinib-intolerant patients), with the median duration of MCyR not reached.